{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:17:11Z","timestamp":1792808231605,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) might be involved in the activation of important pathways related to tumor immune escape, along with programmed death-ligand 1 (PD-L1). Here, we aimed to investigate the correlation between the expression of Siglec-15 and PD-L1 in nasopharyngeal carcinoma (NPC) patients. We determined the expression of PD-L1 via immunohistochemical staining and that of Siglec-15 via immunofluorescence staining in 182 NPC tissue samples. A significant correlation was identified between the PD-L1 and Siglec-15 expression (P\u2009=\u20090.000). Moreover, Kaplan\u2013Meier survival curves showed that PD-L1 expression was associated with improved overall survival (OS) (P\u2009=\u20090.025) and Siglec-15 expression was associated with improved distant failure-free survival (D-FFS) (P\u2009=\u20090.048). Moreover, multivariate Cox analysis showed that PD-L1 and Siglec-15 were independent predictors of OS (P\u2009=\u20090.020) and D-FFS (P\u2009=\u20090.047), respectively. The results of the log-rank test and Cox regression analyses showed that patients exhibiting no PD-L1\/Siglec-15 expression had significant advantages regarding OS, compared to other groups (P\u2009=\u20090.037). PD-L1 and Siglec-15 may represent novel biomarkers for predicting the prognosis of NPC patients. Siglec-15 may be considered as a potential target for the development of therapeutics for NPC treatment in the future.<\/jats:p>","DOI":"10.1038\/s41598-022-13997-2","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T10:04:03Z","timestamp":1655805843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma"],"prefix":"10.1038","volume":"12","author":[{"given":"Ju","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanshan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxia","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongru","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"13997_CR1","volume-title":"Global Cancer Observatory: Cancer Today","author":"J Ferlay","year":"2018","unstructured":"Ferlay, J. et al. Global Cancer Observatory: Cancer Today (International Agency for Research on Cancer, 2018)."},{"issue":"10022","key":"13997_CR2","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S0140-6736(15)00055-0","volume":"387","author":"LK Melvin","year":"2016","unstructured":"Melvin, L. K., Chua, J., Hui, E. P. & Chan, A. T. C. Nasopharyngeal carcinoma. Lancet 387 (10022), 1012\u20131024 (2016).","journal-title":"Lancet"},{"issue":"1","key":"13997_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.14740\/wjon610w","volume":"6","author":"MT Liu","year":"2015","unstructured":"Liu, M. T. et al. Prognostic value of molecular markers and implication for molecular targeted therapies in nasopharyngeal carcinoma: An update in an era of new targeted molecules development. World J. Oncol. 6 (1), 243\u2013261 (2015).","journal-title":"World J. Oncol."},{"key":"13997_CR4","doi-asserted-by":"publisher","first-page":"5605","DOI":"10.2147\/CMAR.S175501","volume":"10","author":"M Wei","year":"2018","unstructured":"Wei, M. et al. Prognostic value of TIGAR and LC3B protein expression in nasopharyngeal carcinoma. Cancer Manage. Res. 10, 5605\u20135616 (2018).","journal-title":"Cancer Manage. Res."},{"issue":"2","key":"13997_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.20892\/j.issn.2095-3941.2018.0141","volume":"16","author":"X Ren","year":"2019","unstructured":"Ren, X. Immunosuppressive checkpoint Siglec-15: A vital new piece of the cancer immunotherapy jigsaw puzzle. Cancer Biol. Med. 16 (2), 205\u2013210 (2019).","journal-title":"Cancer Biol. Med."},{"key":"13997_CR6","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","volume":"35","author":"C Hsu","year":"2017","unstructured":"Hsu, C. et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study. J. Clin. Oncol. 35, 4050\u20134056 (2017).","journal-title":"J. Clin. Oncol."},{"key":"13997_CR7","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","volume":"36","author":"B Ma","year":"2018","unstructured":"Ma, B. et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J. Clin. Oncol. 36, 1412\u20131418 (2018).","journal-title":"J. Clin. Oncol."},{"key":"13997_CR8","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","volume":"19","author":"WF Fang","year":"2018","unstructured":"Fang, W. F. et al. Camrelizumab (SHR\u2212 1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 19, 1338\u20131350 (2018).","journal-title":"Lancet Oncol."},{"issue":"6","key":"13997_CR9","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1097\/MD.0000000000000515","volume":"94","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y. et al. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-Ll) Expression in epithelial-originated cancer: A meta-analysis. Medicine (Baltimore) 94 (6), e515 (2015).","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"13997_CR10","doi-asserted-by":"publisher","first-page":"e157969","DOI":"10.1371\/journal.pone.0157969","volume":"11","author":"VH Lee","year":"2016","unstructured":"Lee, V. H. et al. Correlation of PD-L1 expression of tumor cells with survival outcomes after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma. PLoS ONE 11 (6), e157969 (2016).","journal-title":"PLoS ONE"},{"issue":"3","key":"13997_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12032-015-0501-6","volume":"32","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. Co-expression of PD-I and PD-Ll predicts poor outcome in nasopharyngeal carcinoma. Med. Oncol. 32 (3), 86 (2015).","journal-title":"Med. Oncol."},{"issue":"3","key":"13997_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3892\/mco.2017.1318","volume":"7","author":"Y Li","year":"2017","unstructured":"Li, Y. et al. Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. Mol. Clin. Oncol. 7 (3), 378\u2013382 (2017).","journal-title":"Mol. Clin. Oncol."},{"issue":"1","key":"13997_CR13","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1186\/s12885-019-6276-y","volume":"19","author":"Y Cao","year":"2019","unstructured":"Cao, Y. et al. Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma. BMC Cancer 19 (1), 1022 (2019).","journal-title":"BMC Cancer"},{"key":"13997_CR14","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3389\/fonc.2019.01111","volume":"9","author":"X Liu","year":"2019","unstructured":"Liu, X. et al. Prognostic value of programmed cell death ligand-1 expression in nasopharyngeal carcinoma: A meta-analysis of 1,315 patients. Front. Oncol. 9, 1111 (2019).","journal-title":"Front. Oncol."},{"key":"13997_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12935-019-0863-5","volume":"19","author":"Z Huang","year":"2019","unstructured":"Huang, Z. et al. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: A systematic review and meta-analysis. Cancer Cell Int. 19, 141 (2019).","journal-title":"Cancer Cell Int."},{"key":"13997_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube, J. M. et al. Colocalization of inflammatory response with B7\u2013H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4, 127 (2012).","journal-title":"Sci. Transl. Med."},{"key":"13997_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/1078-0432.CCR-12-2063","volume":"19","author":"M Sznol","year":"2013","unstructured":"Sznol, M. & Chen, L. P. Antagonist antibodies to PD-1 and B7\u2013H1 (PD-L1) in the treatment of advanced human cancer. Clin. Cancer Res. 19, 1021\u20131034 (2013).","journal-title":"Clin. Cancer Res."},{"key":"13997_CR18","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jamaoncol.2016.2450","volume":"2","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. & Chen, L. P. Classification of advanced human cancers based on tumor immunity in the microenvironment (TIME) for cancer immunotherapy. JAMA Oncol. 2, 1403\u20131404 (2016).","journal-title":"JAMA Oncol."},{"key":"13997_CR19","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41591-019-0374-x","volume":"25","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat. Med. 25, 656\u2013666 (2019).","journal-title":"Nat. Med."},{"key":"13997_CR20","doi-asserted-by":"crossref","unstructured":"Siglec-15: An attractive immunotherapy target. Cancer Discov., 10, 7 (2020).","DOI":"10.1158\/2159-8290.CD-NB2019-136"},{"key":"13997_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1807291","author":"BH Li","year":"2020","unstructured":"Li, B. H. et al. Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis. Oncoimmunology. https:\/\/doi.org\/10.1080\/2162402X.2020.1807291 (2020).","journal-title":"Oncoimmunology."},{"issue":"1","key":"13997_CR22","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/s41598-020-79742-9","volume":"11","author":"H Fudaba","year":"2021","unstructured":"Fudaba, H. et al. Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients. Sci. Rep. 11 (1), 1206 (2021).","journal-title":"Sci. Rep."},{"key":"13997_CR23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/nrd3806","volume":"118","author":"A Flemming","year":"2012","unstructured":"Flemming, A. Cancer: PDI makes waves in anticancer immunotherapy!. Nat. Rev. Drug Discov. 118, 601 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"13997_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev.immunol.20.091101.091806","volume":"20","author":"BM Carreno","year":"2002","unstructured":"Carreno, B. M. & Collins, M. The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20, 29\u201353 (2002).","journal-title":"Annu. Rev. Immunol."},{"key":"13997_CR25","doi-asserted-by":"publisher","first-page":"43627","DOI":"10.1038\/srep43627","volume":"7","author":"YJ Zhou","year":"2017","unstructured":"Zhou, Y. J. et al. PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load. Sci. Rep. 7, 43627 (2017).","journal-title":"Sci. Rep."},{"issue":"9","key":"13997_CR26","first-page":"14595","volume":"8","author":"F Xu","year":"2015","unstructured":"Xu, F. et al. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: A meta-analysis. Int. J. Clin. Exp. Med. 8 (9), 14595\u201314603 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"6","key":"13997_CR27","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","volume":"162","author":"S Kleffel","year":"2015","unstructured":"Kleffel, S. et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162 (6), 1242\u20131256 (2015).","journal-title":"Cell"},{"issue":"8","key":"13997_CR28","doi-asserted-by":"publisher","first-page":"e0136023","DOI":"10.1371\/journal.pone.0136023","volume":"10","author":"LH Schmidt","year":"2015","unstructured":"Schmidt, L. H. et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS ONE 10 (8), e0136023 (2015).","journal-title":"PLoS ONE"},{"issue":"1","key":"13997_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.humpath.2015.09.006","volume":"47","author":"MZ Baptista","year":"2016","unstructured":"Baptista, M. Z. et al. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum. Pathol. 47 (1), 78\u201384 (2016).","journal-title":"Hum. Pathol."},{"issue":"7","key":"13997_CR30","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1097\/JTO.0000000000000526","volume":"10","author":"KM Kerr","year":"2015","unstructured":"Kerr, K. M. et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: In what state is this art?. J. Thorac. Oncol. 10 (7), 985\u2013989 (2015).","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"13997_CR31","first-page":"1214","volume":"67","author":"JQ Hao","year":"2020","unstructured":"Hao, J. Q. et al. The significance of Siglec-15 expression in resectable non-small cell lung cancer. Neoplasma 67 (6), 1214\u20131222 (2020).","journal-title":"Neoplasma"},{"key":"13997_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41392-019-0045-x","volume":"4","author":"G Cao","year":"2019","unstructured":"Cao, G., Xiao, Z. & Yin, Z. Normalization cancer immunotherapy: Blocking Siglec-15!. Signal Transduct Target Ther. 4, 10 (2019).","journal-title":"Signal Transduct Target Ther."},{"issue":"1","key":"13997_CR33","first-page":"44","volume":"31","author":"G Murugesan","year":"2021","unstructured":"Murugesan, G. et al. Siglec-15 recognition of sialoglycans on tumor cell lines can occur independently of sialyl Tn antigen expression. Glycobiology 31 (1), 44\u201354 (2021).","journal-title":"Glycobiology"},{"key":"13997_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-1-0716-0430-4_8","volume":"2132","author":"A Alborzian Deh Sheikh","year":"2020","unstructured":"Alborzian Deh Sheikh, A., Akatsu, C. & Tsubata, T. Identification of Siglec Cis-ligands by proximity labeling. Methods Mol. Biol. 2132, 75\u201383 (2020).","journal-title":"Methods Mol. Biol."},{"issue":"22","key":"13997_CR35","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1182\/blood.2019001705","volume":"134","author":"P Jandus","year":"2019","unstructured":"Jandus, P. et al. The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies. Blood 134 (22), 1941\u20131950 (2019).","journal-title":"Blood"},{"issue":"10","key":"13997_CR36","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/PAI.0000000000000698","volume":"26","author":"G Bigras","year":"2018","unstructured":"Bigras, G. et al. Small biopsies misclassify up to 35% of PD-L1 assessments in advanced lung non-small cell lung carcinomas. Appl. Immunohistochem. Mol. Morphol. 26 (10), 701\u2013708 (2018).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"13997_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.07.033","volume":"136","author":"G Wang","year":"2019","unstructured":"Wang, G. et al. PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer. Lung Cancer 136, 1\u20135 (2019).","journal-title":"Lung Cancer"},{"key":"13997_CR38","first-page":"3","volume-title":"Prescribing Recording and Reporting Photon Beam Therapy. ICRU Report 50","author":"ICRU","year":"1993","unstructured":"ICRU. Prescribing Recording and Reporting Photon Beam Therapy. ICRU Report 50 3\u201318 (International Commission on Radiation Units and Measurements, 1993)."},{"key":"13997_CR39","first-page":"4","volume-title":"Prescribing Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50). ICRU Report 61","author":"ICRU","year":"1999","unstructured":"ICRU. Prescribing Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50). ICRU Report 61 4\u201320 (International Commission on Radiation Units and Measurements, 1999)."},{"key":"13997_CR40","first-page":"25","volume-title":"Prescribing Recording and Reporting Photon Beam Therapy. ICRU Report 71","author":"ICRU","year":"2004","unstructured":"ICRU. Prescribing Recording and Reporting Photon Beam Therapy. ICRU Report 71 25\u201334 (International Commission on Radiation Units and Measurements, 2004)."},{"key":"13997_CR41","first-page":"1","volume-title":"Prescribing Recording and Reporting Photon Beam Therapy Intensity-Modulated Radiation Therapy (IMRT). ICRU Report 83","author":"ICRU","year":"2010","unstructured":"ICRU. Prescribing Recording and Reporting Photon Beam Therapy Intensity-Modulated Radiation Therapy (IMRT). ICRU Report 83 Vol. 10, 1\u201334 (International Commission on Radiation Units and Measurements, 2010)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13997-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13997-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13997-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T05:53:32Z","timestamp":1669355612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13997-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["13997"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-13997-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"17 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10401"}}